Is The Current Business Model Of Pharma Companies Outdated When It Comes To Rare Diseases?

By Tim Irfan

The World Orphan Drug Conference held a panel discussion on the importance of collaboration in improving patient outcomes. The panel emphasized the need for collaboration between various stakeholders, including patients, researchers, healthcare professionals, and industry leaders. They discussed the benefits of sharing knowledge, resources, and expertise to accelerate the development of orphan drugs and improve access for patients. The conference highlighted successful collaborations that have led to the development of innovative treatments for rare diseases. Overall, the panel stressed the significance of collaboration in advancing orphan drug research and ultimately improving the lives of patients.